Gyre Therapeutics (GYRE) awards director 40,000 stock options vesting to 2029

Rhea-AI Filing Summary

Gyre Therapeutics director Kirkby Maxwell received a grant of stock options covering 40,000 shares of common stock on August 3, 2026. The options have a $6.1100 exercise price, expire on August 3, 2036, and vest in 36 equal monthly installments through August 3, 2029, subject to continued service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Kirkby Maxwell

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	40,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 40,000 shares (Direct)

Footnotes (1)

1. F1. This option represents a right to purchase a total of 40,000 shares of the Issuer's common stock, which will vest in 36 equal monthly installments through August 3, 2029, subject to the Reporting Person's continued service to the Issuer through each vesting date.

Key Figures

Option Shares Granted: 40000 shares Exercise Price: $6.1100 per share Vesting Schedule: 36 monthly installments +1 more

4 metrics

Option Shares Granted 40000 shares Stock options granted to director on August 3, 2026

Exercise Price $6.1100 per share Conversion or exercise price for the stock option

Vesting Schedule 36 monthly installments Vests in 36 equal monthly installments through August 3, 2029

Expiration Date August 3, 2036 Expiration date of the granted stock option

Key Terms

Stock Option (Right to Buy), exercise price, vesting, expiration date

4 terms

Stock Option (Right to Buy) financial

"Security title reported as "Stock Option (Right to Buy)" for the award"

exercise price financial

"Option reported with a conversion or exercise price of $6.1100 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"Option will vest in 36 equal monthly installments through August 3, 2029"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"Option carries an expiration date reported as 2036-08-03"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/04/2026 - 08:40 PM Accepted by SEC EDGAR 08/04/2026 - 08:39 PM Learn about SEC filing dates

FAQ

What insider transaction involving GYRE did director Kirkby Maxwell report?

Director Kirkby Maxwell reported receiving a grant of stock options on August 3, 2026, covering 40,000 shares of Gyre Therapeutics common stock. The award is a compensation-related acquisition, not an open-market trade.

How many shares are covered by Kirkby Maxwell's GYRE stock options?

The granted stock option gives Kirkby Maxwell the right to purchase 40,000 shares of Gyre Therapeutics common stock. These shares are underlying the option and will become exercisable as the award vests over time.

What is the exercise price and expiration date of Maxwell's GYRE options?

Maxwell’s option has an exercise price of $6.1100 per share and an expiration date of August 3, 2036. He may exercise vested portions of the option any time before that expiration, subject to plan terms.

How do the GYRE stock options granted to Kirkby Maxwell vest?

The option will vest in 36 equal monthly installments through August 3, 2029. Vesting is conditioned on Maxwell’s continued service to Gyre Therapeutics through each vesting date, meaning unvested portions could be forfeited if service ends.

Is Kirkby Maxwell's GYRE Form 4 transaction a purchase or a grant?

The Form 4 reports a grant/award acquisition of stock options, coded “A,” rather than a market purchase. Maxwell did not buy shares in the open market; he received options as part of his director compensation.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kirkby Maxwell

(Last) (First) (Middle)

C/O GYRE THERAPEUTICS, INC.

12730 HIGH BLUFF DRIVE, SUITE 250

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
GYRE THERAPEUTICS, INC. [ GYRE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$6.11	08/03/2026		A		40,000		(1)	08/03/2036	Common Stock	40,000	$0	40,000	D

Explanation of Responses:

1. This option represents a right to purchase a total of 40,000 shares of the Issuer's common stock, which will vest in 36 equal monthly installments through August 3, 2029, subject to the Reporting Person's continued service to the Issuer through each vesting date.

	/s/ Thomas Eastling, as attorney-in-fact for Maxwell Kirkby	08/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)